News
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
Formycon publishes study results in peer-reviewed journal analyzing biosimilar candidate FYB206 and Keytruda, showing high similarity in structure and function. Results support ongoing clinical trials -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH releases an update on Formycon AG, with analyst Simon Scholes reiterating a BUY rating and raising the price target from EUR 80 to EUR 82. The approval of the biosimilar FYB202 in the EU and US contributes to the positive outlook on Formycon's market share prospects -
-
-
COMMUNIQUÉ DE PRESSE
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for FYB202/OtulfiTM (ustekinumab-aauz) to treat several conditions including Crohn’s disease and psoriasis, expanding biosimilar market presence -
